Iqvia Holdings, Inc. · NYSE:IQV
Iqvia — IQVIA Life Sciences Innovation Forum (September 2022)
16 slides from Iqvia's conference presentation, Sep 12, 2022
Slide 1: IQVIA Life Sciences Innovation Forum: Set-up Slides: Addressing Unmet Healthcare Needs
IQVIA Life Sciences Innovation Forum S e t - u p S l i d e s : Ad d r e s s i n g U n m e t H e a l t h c a r e Needs September 12, 2022 Copyright © 2021 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.
Slide 2: Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations
Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations, and scientific bottlenecks 1
Slide 3: Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations
Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations, and scientific bottlenecks Member states should “foster R&D [in] areas…insufficiently addressed by commercial research (e.g. AMR [antimicrobial resistance) and [for] patient populations normal
Slide 4: Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations
Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations, and scientific bottlenecks Member states should “foster R&D [in] areas…insufficiently addressed by commercial research (e.g. AMR [antimicrobial resistance) and [for] patient populations normal
Slide 5: Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations
Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations, and scientific bottlenecks Member states should “foster R&D [in] areas…insufficiently addressed by commercial research (e.g. AMR [antimicrobial resistance) and [for] patient populations normal
Slide 6: Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations
Perceptions of global unmet healthcare need focus on infectious diseases, female and pediatric populations, and scientific bottlenecks Member states should “foster R&D [in] areas…insufficiently addressed by “Lack of proper or systematic funding is particularly commercial research (e.g. AMR [antimicr
Slide 7: Novel active substances have seen growth in Orphan/rare disease therapies and new frontiers
Novel active substances (NASs) have seen growth in Orphan/rare disease therapies and a refocusing on new frontiers and innovative therapies 90 All others (143) Global NAS launches 2012-2021 80 Respiratory (14) Dermatologics (17) 70 Anti-diabetics (24) 60 Immunology (23) Cardiovascular (23) 50 COVID-
Slide 8: Novel active substances have seen growth in Orphan/rare disease therapies and new frontiers
Novel active substances (NASs) have seen growth in Orphan/rare disease therapies and a refocusing on new frontiers and innovative therapies 90 60% All others (143) Global NAS launches 2012-2021 80 Respiratory (14) 50% Dermatologics (17) 70 Anti-diabetics (24) 60 40% Immunology (23) Cardiovascular (2
Slide 9: The number of pipeline products Phase I to regulatory submission has grown, 2011−2021
The number of pipeline products Phase I to regulatory submission has grown, 2011−2021 but with little shift in therapeutic area focus 3,394 6,085 100% 90% All others 6% 6% 4% 4% Endocrinology 80% 4% 4% Respiratory 5% 5% 70% 4% 4% Hematologic agents 5% 6% 3% 3% Pain 60% 5% 5% Dermatologics 5% 5% 50%
Slide 10: Cancer trials focus on metastatic or advanced cancers but early cancer and vaccine trials have doubled
Cancer trials focus on metastatic or advanced cancers but trials for early cancer and vaccines have more than doubled in 10 years Oncology trial starts by the targeted stage of disease Early vs metastatic trial starts Early cancer and vaccine trial starts 2,500 189 2,000 152 156 142 1,500 113 107 88
Slide 11: About one fifth of all trials for novel therapies are focused on early intervention
About one fifth of all trials for novel therapies are focused on early intervention, disease modification or prevention in some disease areas 250 100% Global Unapproved therapies in ongoing PII/II and III trials 90% Treatment/Late/Unspe 200 cified 80% Mild/early/preventative 70% 61% 150 60% 50% 100
Slide 12: The next-generation biotherapeutic pipeline is focused on gene editing, CAR-T and other cell therapies
The next-generation biotherapeutic pipeline is focused on gene editing, CAR-T and other cell therapies Next-generation biotherapeutics Phase I to regulatory submission pipeline by mechanism, 2011-2021 900 800 Other 700 600 RNA therapeutics 500 CAR-T & NK cell therapy 400 300 Cell therapy 200 Gene ed
Slide 13: Socioeconomic and educational barriers to access can help health systems derive more value from medicines
Socioeconomic and educational barriers to access can help health systems derive more value from medicines, but these are challenging for Life Science Companies to influence Awareness Acceptance Accessibility Availability Affordability Adherence "I don’t have confidence in “I cannot reach the “I cann
Slide 14: Across essential innovative medicine groups there are significant differences in per capita use
Across essential innovative medicine groups there are significant differences in per capita use Average Utilization of Essential Innovative Medicines Across All Groups, Europe Average=100 250 Average DDD per Capita Index 200 (Europe Average = 100) 150 100 50 0 Note: European average excludes null va
Slide 15: Multiple underlying drivers of differences in use of Essential Innovative Medicines require further research
Multiple underlying drivers of differences in use of Essential Innovative Medicines require further research NON-EXHAUSTIVE EPIDEMIOLOGY DIAGNOSTICS Prevalence and disease burden Avaialbility and use of related diagnositcis VALUE ASSESSMENT MEDICAL PRACTICE Incremental clinical benefits Real world p
Slide 16: Addressing Unmet Healthcare Needs: Areas for discussion
Addressing Unmet Healthcare Needs Areas for discussion Balancing Disease and Innovation Priorities How can stakeholders balance patient and population interests between rare and common diseases, and between incremental and breakthrough innovations? Identifying New Pathways How can research efforts m
IQVIA Holdings — IQVIA Life Sciences Innovation Forum (September 2022) on 6ix